12 results about "Thrombogenicity" patented technology

The present disclosure relates to inhibition of platelet absorption. Cardiovascular grafts with highly reduced thrombosis are provided. The cardiovascular graft is an electrospun nonwoven web produced from a supramolecular polymer of large diameter fibers. The cardiovascular graft can be implanted in a human body as a vascular graft to allow blood vessel bypass / reconstruction, or repeated venous access for dialysis treatment, as well as other small diameter vascular disorders.

A zwitterionic polyurethane additive, a base polymer comprising zwitterionic polyurethane additive, a medical device comprising an admixture of a base polymer and zwitterionic polyurethane additive, a method of reducing a thrombogenic and / or bacterial adhesion property of an admixture of a base polymer and zwitterionic polyurethane additive, are disclosed. The zwitterionic polyurethane additive is a reaction product of an isocyanate group terminated polyurethane prepolymer with tertiary amine alcohols, followed by reaction with at least one heterocycle selected from the group consisting of a sultone, a lactone, or a 2-alkoxy-2-oxo-1,3,2-dioxaphospholane.

The present invention relates to chimeric aGPCR and uses thereof. By redirecting the intracellular signal response to the desired target, the chimeric aGPCR may be used in a manner similar to a chimeric antigen receptor. The chimeric aGPCR may also bind to platelets or engineered non-thrombogenic platelets for targeted drug delivery.

A fluorinated thermoplastic polyurethane (FTPU) for use with medical devices is disclosed. The FTPU may include a soft segment (which may include a polyol), a hard segment (which may include a diisocyanate), and a chain extender. At least one fluorinated portion may be present in the FTPU. The fluorinated portion(s) may include a fluorinated polyol, a fluorinated diisocyanate, a fluorinated chain extender, or a combination thereof. The fluorinated portion(s) may be present in a total amount of 5% to 50% by weight of the FTPU. The FTPU may be used to reduce the coefficient of friction or reduce thrombogenicity of a medical device. A composition of matter may be provided, including a FTPU which may be a reaction product of a polyol, a diisocyanate, a chain extender, and optionally, a catalyst, where at least one of the polyol, diisocyanate, and / or chain extender may be fluorinated.

A fluorinated thermoplastic polyurethane (FTPU) for use with medical devices is disclosed. The FTPU may include a soft segment (which may include a polyol), a hard segment (which may include a diisocyanate), and a chain extender. At least one fluorinated portion may be present in the FTPU. The fluorinated portion(s) may include a fluorinated polyol, a fluorinated diisocyanate, a fluorinated chain extender, or a combination thereof. The fluorinated portion(s) may be present in a total amount of 5% to 50% by weight of the FTPU. The FTPU may be used to reduce the coefficient of friction or reduce thrombogenicity of a medical device. A composition of matter may be provided, including a FTPU which may be a reaction product of a polyol, a diisocyanate, a chain extender, and optionally, a catalyst, where at least one of the polyol, diisocyanate, and / or chain extender may be fluorinated.

The invention belongs to the technical field of immunodetection analysis, and discloses a kit for quantitative detection of a thrombin-antithrombin III compound and a preparation method of the kit. The kit comprises a magnetic bead working solution, an acridinium ester marker working solution, a biotin marker working solution, a TAT calibrator and a TAT quality control product, and quantitative detection of TAT is realized by combining a double-antibody sandwich method with a chemiluminescence technology. The method overcomes the defects that an existing fluorescence immunoassay method is low in repeatability, and an immunoturbidimetry method is high in requirement for specimens and limited in low-concentration detection capacity, and has the advantages of being high in specificity, sensitivity and accuracy and easy, convenient and rapid to operate. The method can be used for clinical auxiliary diagnosis of thrombogenic diseases such as disseminated intravascular coagulation (DIC) and venous thromboembolism (VTE), and provides a basis for blood coagulation state evaluation and clinical decision making.

The invention provides intravascular devices for treating certain medical conditions such as edema without causing thrombosis. The intravascular devices of the disclosure include non-thrombogenic surfaces that improve blood compatibility by reducing device-related thrombus formation and inflammatory reactions. The non-thrombogenic surfaces may include surface topographies (e.g., surface roughness) and modified chemistries (e.g., coatings and / or treatments), which prevent thrombosis by reducing local shear forces and inhibiting adhesion of blood clotting factors.

The invention relates to the field of angiographic catheter performance detection, is used for solving the problem that the ability to detect the change condition in the catheter detection process is insufficient when the angiographic catheter performance is tested, and particularly relates to an angiographic catheter application performance detection system and method. Testing a tail-section acquisition module and a process result output module; in the angiographic catheter testing process, the angiographic catheter parameters in the process are continuously collected, the real-time change condition of the angiographic catheter in the whole testing process is obtained, the defects that in traditional detection, data at a single time point are in one piece, and the dynamic performance of the catheter cannot be reflected are overcome, meanwhile, the deformation degree of the catheter is collected, and the accuracy of the dynamic performance of the catheter is improved. The out-of-round situation of the angiographic catheter in the using process is simulated, the situation that deformation of the angiographic catheter is not uniform when the angiographic catheter bears pressure can be known more accurately, and the situation that thrombus formation is increased due to the fact that deformation of the angiographic catheter is not uniform in the actual using process is prevented.

The present invention relates to metal-based coronary stents designed to reduce or eliminate the release of metal ions into the physiological environment. The invention further provides a method of manufacturing such stents, wherein a metal alloy tube is laser-cut to form a stent platform comprising longitudinal and circumferential struts, followed by cleaning, electropolishing, heat-treatment, passivation and ultrasonic ethanol cleaning. The processed platform is coated with a ceramic layer of titanium nitride having a uniform thickness in the range of 200-3000 nm using physical vapor deposition. The titanium nitride coating acts as a biocompatible ion-barrier, improving hemocompatibility and reducing complications such as restenosis, inflammation, thrombogenicity, and long-term metal ion elution, while maintaining mechanical integrity and radial strength required for vascular deployment.

The invention provides intravascular devices for treating certain medical conditions such as edema without causing thrombosis. The intravascular devices of the disclosure include non-thrombogenic surfaces that improve blood compatibility by reducing device-related thrombus formation and inflammatory reactions. The non-thrombogenic surfaces may include surface topographies (e.g., surface roughness) and modified chemistries (e.g., coatings and / or treatments), which prevent thrombosis by reducing local shear forces and inhibiting adhesion of blood clotting factors.

The invention provides intravascular devices for treating certain medical conditions such as edema without causing thrombosis. The intravascular devices of the disclosure include non-thrombogenic surfaces that improve blood compatibility by reducing device-related thrombus formation and inflammatory reactions. The non-thrombogenic surfaces may include surface topographies (e.g., surface roughness) and modified chemistries (e.g., coatings and / or treatments), which prevent thrombosis by reducing local shear forces and inhibiting adhesion of blood clotting factors.